Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: A systematic review and economic evaluation

Jones, L; Griffin, S; Palmer, S; Main, C; Orton, V; Sculpher, M; Sudlow, C; Henderson, R; Hawkins, N; Riemsma, R; (2004) Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: A systematic review and economic evaluation. Health technology assessment (Winchester, England), 8 (38). iii-iv, 1-196. ISSN 1366-5278 http://researchonline.lshtm.ac.uk/id/eprint/2545583

Permanent Identifier

Use this permanent URL when citing or linking to this resource.

http://researchonline.lshtm.ac.uk/id/eprint/2545583

Abstract

Item Type Article
Keywords *blood vessel occlusion/dm [Disease Management], *blood vessel occlusion/dt [Drug Therapy], *blood vessel occlusion/pc [Prevention], *clopidogrel/ae [Adverse Drug Reaction], *clopidogrel/cb [Drug Combination], *clopidogrel/cm [Drug Comparison], *clopidogrel/ct [Clinical Trial], *clopidogrel/do [Drug Dose], *clopidogrel/dt [Drug Therapy], *clopidogrel/pd [Pharmacology], *clopidogrel/pe [Pharmacoeconomics], *dipyridamole/ae [Adverse Drug Reaction], *dipyridamole/cb [Drug Combination], *dipyridamole/cm [Drug Comparison], *dipyridamole/ct [Clinical Trial], *dipyridamole/do [Drug Dose], *dipyridamole/dt [Drug Therapy], *dipyridamole/pd [Pharmacology], *dipyridamole/pe [Pharmacoeconomics], *dipyridamole/pr [Pharmaceutics], *secondary prevention, acetylsalicylic acid plus dipyridamole, acetylsalicylic acid/ae [Adverse Drug Reaction], acetylsalicylic acid/cb [Drug Combination], acetylsalicylic acid/cm [Drug Comparison], acetylsalicylic acid/ct [Clinical Trial], acetylsalicylic acid/do [Drug Dose], acetylsalicylic acid/dt [Drug Therapy], acetylsalicylic acid/pd [Pharmacology], acetylsalicylic acid/pe [Pharmacoeconomics], antithrombocytic agent/ae [Adverse Drug Reaction], antithrombocytic agent/cb [Drug Combination], antithrombocytic agent/cm [Drug Comparison], antithrombocytic agent/ct [Clinical Trial], antithrombocytic agent/do [Drug Dose], antithrombocytic agent/dt [Drug Therapy], antithrombocytic agent/pd [Pharmacology], antithrombocytic agent/pe [Pharmacoeconomics], antithrombocytic agent/pr [Pharmaceutics], artery disease/dm [Disease Management], artery disease/dt [Drug Therapy], artery disease/pc [Prevention], atherosclerosis/dt [Drug Therapy], bibliographic database, bleeding/si [Side Effect], blood toxicity/si [Side Effect], brain hemorrhage/si [Side Effect], cause of death, cerebrovascular accident/dm [Disease Management], cerebrovascular accident/dt [Drug Therapy], cerebrovascular accident/pc [Prevention], clinical study, clinical trial, confidence interval, controlled clinical trial, controlled study, cost effectiveness analysis, death, diarrhea/si [Side Effect], disability, dizziness/si [Side Effect], drug dose regimen, drug efficacy, drug eruption/si [Side Effect], drug release, gastrointestinal hemorrhage/si [Side Effect], headache/si [Side Effect], health economics, heart infarction/dm [Disease Management], heart infarction/dt [Drug Therapy], heart infarction/pc [Prevention], human, incidence, indigestion/si [Side Effect], intermethod comparison, lifespan, liver dysfunction/si [Side Effect], medical literature, model, monotherapy, nausea/si [Side Effect], neutropenia/si [Side Effect], placebo, quality of life, review, risk assessment, risk reduction, sensitivity analysis, statistical significance, systematic review, thrombocytopenia/si [Side Effect], thrombotic thrombocytopenic purpura/si [Side Effec, transient ischemic attack/dm [Disease Management], transient ischemic attack/dt [Drug Therapy], transient ischemic attack/pc [Prevention], vascular disease/dm [Disease Management], vascular disease/dt [Drug Therapy], vascular disease/pc [Prevention], vomiting/si [Side Effect], Aspirin, economics, therapeutic use, Cost-Benefit Analysis, Delayed-Action Preparations, Diarrhea, chemically induced, Dipyridamole, adverse effects, economics, therapeutic use, Drug Costs, statistics & numerical data, Drug Eruptions, etiology, Dyspepsia, chemically induced, Evidence-Based Medicine, Hemorrhage, chemically induced, Humans, Ischemia, economics, etiology, mortality, prevention & control, Models, Econometric, Nausea, chemically induced, Platelet Aggregation Inhibitors, adverse effects, economics, therapeutic use, Research Design, standards, Risk Factors, Ticlopidine, adverse effects, analogs & derivatives, economics, therapeutic use, Treatment Outcome, Vascular Diseases, economics, etiology, mortality, prevention & control, Vomiting, chemically induced
Faculty and Department Faculty of Public Health and Policy > Dept of Health Services Research and Policy
Research Centre Centre for Statistical Methodology
PubMed ID 15461876

Share

Download

Filename: Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events.pdf

Licence: Copyright the publishers

Download
[img]

Downloads

View details

Google Scholar